When good immune cells like neutrophils and monocytes (which are usually immune system defenders) go rogue and become "pathologically activated", they can become something called myeloid-derived suppressor cells, or MDSCs. Instead of protecting us, these MDSCs help multiple myeloma grow. In this show, Dr. Vogl and Dr. Nefedova teach us what MDSCs are and how they work and how a new therapy called tasquinimod could help slow down myeloma growth. Learn more about this clinical trial using tasquinimod with ixazomib, lenalidomide and dex in combination to improve myeloma outcomes and slow myeloma growth.
Thanks to our episode sponsor
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113